Rapid Response to Pembrolizumab in a Chemo-Refractory Testicular Germ Cell Cancer with Microsatellite Instability-High

References

• Hanna NH, Einhorn LH. Testicular cancer–discoveries and updates. N Engl J Med. 2014;371:2005–2016. doi:10.1056/NEJMra1407550
   PubMed Web of Science ®Google Scholar
• Feldman DR, Patil S, Trinos MJ, et al. Progression-free and overall survival in patients with relapsed/refractory germ cell tumors treated with single-agent chemotherapy: endpoints for clinical trial design. Cancer. 2012;118:981–986. doi:10.1002/cncr.26375
   PubMed Web of Science ®Google Scholar
• Oing C, Alsdorf WH, von Amsberg G, et al. Platinum-refractory germ cell tumors: an update on current treatment options and developments. World J Urol. 2017;35:1167–1175. doi:10.1007/s00345-016-1898-z
   PubMed Web of Science ®Google Scholar
• Shah S, Ward JE, Bao R, et al. Clinical response of a patient to anti-PD-1 immunotherapy and the immune landscape of testicular germ cell tumors. Cancer Immunol Res. 2016;4:903–909. doi:10.1158/2326-6066.CIR-16-0087
   PubMed Web of Science ®Google Scholar
• Zschäbitz S, Lasitschka F, Jäger D, et al. Activity of immune checkpoint inhibition in platinum refractory germ-cell tumors. Ann Oncol. 2016;27:1356–1360. doi:10.1093/annonc/mdw146
   PubMed Web of Science ®Google Scholar
• Chi EA, Schweizer MT. Durable response to immune checkpoint blockade in a platinum-refractory patient with nonseminomatous germ cell tumor. Clin Genitourin Cancer. 2017;15:e855–e857. doi:10.1016/j.clgc.2017.04.005
   PubMed Web of Science ®Google Scholar
• Aksun MS, Ucgul E, Sahin TK, et al. Nivolumab for the salvage treatment of desperate germ cell tumor: a case report. J Oncol Pharm Pract. 2020;6:1078155220977638. doi:10.1177/1078155220977638
   Google Scholar
• Zschäbitz S, Lasitschka F, Hadaschik B, et al. Response to anti-programmed cell death protein-1 antibodies in men treated for platinum refractory germ cell cancer relapsed after high-dose chemotherapy and stem cell transplantation. Eur J Cancer. 2017;76:1–7. doi:10.1016/j.ejca.2017.01.033
   PubMed Web of Science ®Google Scholar
• Necchi A, Giannatempo P, Raggi D, et al. An open-label randomized Phase 2 study of durvalumab alone or in combination with tremelimumab in patients with advanced germ cell tumors (APACHE): results from the first planned interim analysis. Eur Urol. 2019;75:201–203. doi:10.1016/j.eururo.2018.09.010
   PubMed Web of Science ®Google Scholar
• Mego M, Svetlovska D, Chovanec M, et al. Phase II study of avelumab in multiple relapsed/refractory germ cell cancer. Invest New Drugs. 2019;37:748–754. doi:10.1007/s10637-019-00805-4
   PubMed Web of Science ®Google Scholar
• Adra N, Einhorn LH, Althouse SK, et al. Phase II trial of pembrolizumab in patients with platinum refractory germ-cell tumors: a Hoosier Cancer Research Network Study GU14-206. Ann Oncol. 2018;29:209–214. doi:10.1093/annonc/mdx680
   PubMed Web of Science ®Google Scholar
• Tsimberidou AM, Vo HH, Subbiah V, et al. Pembrolizumab in patients with advanced metastatic germ cell tumors. Oncologist. 2021;26(7):558. doi:10.1002/onco.13682
   PubMed Web of Science ®Google Scholar
• Carbognin L, Pilotto S, Milella M, et al. Differential activity of nivolumab, pembrolizumab and MPDL3280A according to the tumor expression of programmed death-ligand-1 (PD-L1): sensitivity analysis of trials in melanoma, lung and genitourinary cancers. PLoS One. 2015;10(6):e0130142. doi:10.1371/journal.pone.0130142
   PubMed Web of Science ®Google Scholar
• Shen X, Zhao B. Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis. BMJ. 2018;362:k3529. doi:10.1136/bmj.k3529
   PubMed Web of Science ®Google Scholar
• Yarchoan M, Hopkins A, Jaffee EM. Tumor mutational burden and response rate to PD-1 inhibition. N Engl J Med. 2017;377:2500–2501. doi:10.1056/NEJMc1713444
   PubMed Web of Science ®Google Scholar
• Cárcano FM, Lengert AH, Vidal DO, et al. Absence of microsatellite instability and BRAF (V600E) mutation in testicular germ cell tumors. Andrology. 2016;4:866. doi:10.1111/andr.12200
   PubMed Web of Science ®Google Scholar
• Necchi A, Bratslavsky G, Corona RJ, et al. Genomic characterization of testicular germ cell tumors relapsing after chemotherapy. Eur Urol Focus. 2020;6:122–130. doi:10.1016/j.euf.2018.07.013
   PubMedGoogle Scholar
• Honecker F, Wermann H, Mayer F, et al. Microsatellite instability, mismatch repair deficiency, and BRAF mutation in treatment-resistant germ cell tumors. J Clin Oncol. 2009;27:2129–2136. doi:10.1200/JCO.2008.18.8623
   PubMed Web of Science ®Google Scholar
• Mayer F, Wermann H, Albers P, et al. Histopathological and molecular features of late relapses in non-seminomas. BJU Int. 2011;107:936–943. doi:10.1111/j.1464-410X.2010.09631.x
   PubMed Web of Science ®Google Scholar
• Leighl NB, Page RD, Raymond VM, et al. Clinical utility of comprehensive cell-free DNA analysis to identify genomic biomarkers in patients with newly diagnosed metastatic non-small cell lung cancer. Clin Cancer Res. 2019;25::4691–4700. doi:10.1158/1078-0432.CCR-19-0624
   PubMed Web of Science ®Google Scholar
• Willis J, Lefterova M, Artyomenko A, et al. Validation of microsatellite instability detection using a comprehensive plasma-based genotyping panel. Clin Cancer Res. 2019;25:7035–7045. doi:10.1158/1078-0432.CCR-19-1324
   PubMed Web of Science ®Google Scholar
• Bando H, Okamoto W, Fukui T, et al. Utility of the quasi-monomorphic variation range in unresectable metastatic colorectal cancer patients. Cancer Sci. 2018;109:3411–3415. doi:10.1111/cas.13774
   PubMed Web of Science ®Google Scholar
• Fankhauser CD, Curioni-Fontecedro A, Allmann V, et al. Frequent PD-L1 expression in testicular germ cell tumors. Br J Cancer. 2015;113:411–413. doi:10.1038/bjc.2015.244
   PubMed Web of Science ®Google Scholar
• Cierna Z, Mego M, Miskovska V, et al. Prognostic value of programmed-death-1 receptor (PD-1) and its ligand 1 (PD-L1) in testicular germ cell tumors. Ann Oncol. 2016;27:300–305. doi:10.1093/annonc/mdv574
   PubMed Web of Science ®Google Scholar
• Birkhead BM, Scott RM. Spontaneous regression of metastatic testicular cancer. Cancer. 1973;32:125–129. doi:10.1002/1097-0142(197307)32:1<125::AID-CNCR2820320117>3.0.CO;2-Y
   PubMed Web of Science ®Google Scholar
• Musser JE, Przybycin CG, Russo P. Regression of metastatic seminoma in a patient referred for carcinoma of unknown primary origin. Nat Rev Urol. 2010;7:466–470. doi:10.1038/nrurol.2010.99
   PubMed Web of Science ®Google Scholar
• Balzer BL, Ulbright TM. Spontaneous regression of testicular germ cell tumors: an analysis of 42 cases. Am J Surg Pathol. 2006;30:858–865. doi:10.1097/01.pas.0000209831.24230.56
   PubMed Web of Science ®Google Scholar